FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology.

Li, Dan; Kusko, Rebecca; Ning, Baitang; Tong, Weida; Johann, Donald J; Xu, Joshua

Li, Dan; Kusko, Rebecca; Ning, Baitang; Tong, Weida; Johann, Donald J; Xu, Joshua.

Afiliação

Li D; Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA.
Kusko R; Immuneering Corporation, Cambridge, MA, USA.
Ning B; Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA.
Tong W; Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA.
Johann DJ; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Xu J; Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA.

Precis Cancer Med ; 42021 Dec.

Article em En | MEDLINE | ID: mdl-35282311

Palavras-chave

Quality control; cancer; deep targeted sequencing; precision oncology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Precis Cancer Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google